Launch of "Simponi®”, a human TNFα monoclonal antibody in Indonesia

September 20, 2012 Press Release Mitsubishi Tanabe Pharma Corporation Launch of "Simponi ®”, a human TNFα monoclonal antibody in Indonesia Osaka, Japan, September 20, 2012 --- Mitsubishi Tanabe Pharma Corporation (President & CEO: Michihiro Tsuchiya) ann ounced today that its consoli dated subsidiary, P.T.Tanabe Indonesia (head office: Jakarta, Indonesia), started marketing a human TNF α monoclonal antibody, “golimumab (genetical recombination)” under the brand name, Simponi ® Subcutaneous Injection, as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, in Indonesia on September 3. Simponi® was discovered and developed by Janss en Biotech, Inc. as a treatment for inflammatory autoimmune diseases involving TNFα such as rheumatoid arthritis, and was first approved in the U.S. and Europe in 2009. It is approved in more than 50 countries. In Japan, Janssen Pharmaceutical K.K. obtained the manufacturing and ma rketing license in July 2011 for the treatment of rheumatoid ar thritis (including prevention of articular structural damage) in cases showing inadequate response to conventional therapies. Mitsubishi Tanabe Pharma and Janssen Pharmaceutical K.K. started co-marketing Simponi® in September 2011. Through the launch of Simponi ® recently, Mitsubishi Tanabe Pharma expects to expand therapeutic options for patients of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in Indonesia, and will contribute to improving the treatment for a larger number of patients. <<Contact for Inquiries>> Mitsubishi Tanabe Pharma Corporation Corporate Communications Department Phone: +81-6-6205-5211

The release as fetched from its publisher. tanabe-pharma.com ↗